Key Highlights

  • Veea (NASDAQ:VEEA) jumped 49.74% to USD 5.79 in the October 9, 2026 session, with published reports linking the move to a company statement on Nasdaq listing compliance that the company release and 8-K could not confirm.
  • Vivakor (NASDAQ:VIVK) rose 37.41% to USD 5.51 after a 1-for-15 reverse split, with a reported USD 40 million Direct Midstream letter of intent unconfirmed and the company's own release describing only a non-binding indication of interest.
  • Duos Technologies (NASDAQ:DUOT) fell 7.69% to USD 7.20 as reported coverage began with a Neutral rating and a USD 9.50 target, a call that looks mild and does not clearly explain the drop.
  • bioAffinity Technologies (NASDAQ:BIAF) fell 8.69% to USD 5.15 even after a positive October 8 Japan Patent release, which suggests that financing, warrants and a tiny float matter more than news for this company.

Veea (NASDAQ:VEEA): Reported Nasdaq Compliance Statement

Veea (NASDAQ:VEEA) gained 49.74% to USD 5.79 in the October 9, 2026 session. The likely catalyst is a company statement, reported by published sources, that it meets Nasdaq's continued listing requirements. The company release and the 8-K were not located and the rule was not named, so the detail is labelled reported. The filings show two listing issues: a bid price deadline of September 28, 2026 and board and committee shortfalls after a director died on June 1. A 1-for-20 reverse split took effect on August 28, so earlier prices are not comparable. The financial base is thin. Second quarter 2026 Revenue was USD 176,221, the net loss was USD 4,025,910 and cash was USD 886,966, with an accumulated Deficit of USD 233.2 million. Published reports described a non-binding Merger term sheet with NovaGen Group, which is not a definitive agreement. Total liabilities fell to USD 22,031,313 from USD 37,972,505 at December 31, 2025, yet the company said it intends to regain compliance without guarantee. New Capital would likely dilute holders of Veea (NASDAQ:VEEA).

Vivakor (NASDAQ:VIVK): Reverse Split and a Disputed Acquisition Headline

Vivakor (NASDAQ:VIVK) gained 37.41% to USD 5.51 in the October 9, 2026 session. The likely catalyst is a published headline about a letter of intent for a USD 40 million acquisition of Direct Midstream, but the text was not read, so the date and terms are reported. What is confirmed is an October 6, 2026 company release describing a non-binding indication of interest in the Midland, Texas water midstream business, with no price and no assurance of a definitive agreement. A 1-for-15 reverse split took effect on October 5, cutting shares outstanding from about 8,981,898 to about 598,794. The USD 5.51 quote is therefore not comparable with earlier prices. A 1-for-20 split had already taken effect on July 17, 2026, and published market data showed a close of USD 0.51 before the latest one. The Business is mostly Crude Oil Supply and trading. Second quarter revenue rose 10% to USD 32.1 million, gross Margin was 20.7% and the net loss narrowed to about USD 2.8 million. Risks include dilution, listing compliance and a deal that may never become definitive, and with so few shares, quotes for Vivakor (NASDAQ:VIVK) can move sharply.

Duos Technologies (NASDAQ:DUOT): Mild Analyst Initiation, Back-Loaded Plan

Duos Technologies (NASDAQ:DUOT) fell 7.69% to USD 7.20 in the October 9, 2026 session, with a Market Value near USD 227 million. Reportedly, Chardan Capital initiated coverage that day with a Neutral rating and a USD 9.50 target, about 21.8% above the prior USD 7.80 price. That is not an obviously negative call, so the link to the drop is unproven, and no company release dated October 8 or 9 was found. The second quarter release of August 17 reported revenue up 30% to USD 6.18 million and cash of USD 112.3 million. The company described AI Data Center hosting agreements, including a USD 111 million contract for 10 MW in Columbus, Georgia, and reaffirmed 2026 revenue above USD 50 million. Cash rose from USD 15.5 million at the end of 2025, helped by a USD 55 million registered direct offering and USD 50.4 million from asset sales. First-half revenue was only USD 8.32 million, so the plan is back-loaded, and Net Income came mainly from an Investment gain, not operations. Delays or new financing would hurt Duos Technologies (NASDAQ:DUOT).

bioAffinity Technologies (NASDAQ:BIAF): Patent News Fails to Lift Shares

bioAffinity Technologies (NASDAQ:BIAF) fell 8.69% to USD 5.15 in the October 9, 2026 session, with a market value near USD 6 million. The latest company release, dated October 8, said Japan's patent office signaled it intends to grant a patent covering a method of predicting lung cancer likelihood with CyPath Lung. That news is positive, and the company says it holds 22 awarded patents and 36 pending applications. No release explaining the drop was found, so this is labelled a no-catalyst move. The company did a 1-for-15 reverse split on August 24 and priced a private Placement of about USD 4.0 million on August 12, with warrants attached. First-half CyPath Lung testing revenue rose 159% to about USD 835,000, yet first-half total revenue of USD 2.86 million was below USD 3.12 million a year earlier. Second quarter revenue was USD 1.5 million, up 19%, the net loss was USD 3.4 million and cash was USD 2.4 million at June 30, before the August proceeds. A tiny float, steady cash needs and Warrant overhang are the likelier drivers, though that is an inference. Further offerings could dilute bioAffinity Technologies (NASDAQ:BIAF).

Where Things Stand

Two of these microcaps surged and two fell in the October 9, 2026 session, and in each case the stated catalyst is incomplete. Veea (NASDAQ:VEEA) rose on a reported item that the filings could not confirm. Vivakor (NASDAQ:VIVK) did likewise. Duos Technologies (NASDAQ:DUOT) fell without a clear company trigger. So did bioAffinity Technologies (NASDAQ:BIAF). Reverse splits, thin finances and dilution risk link all four, so any quote can reverse quickly. Figures here are session snapshots rather than official closes, so they should be rechecked against final data.